RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth

Neoplasia (United States)

Volumn 17, Issue 10, 2015, Pages 776-788

  Solga, Anne C ^a   Pong, Winnie W ^a   Kim, Keun Young ^b   Cimino, Patrick J ^a   Toonen, Joseph A ^a   Walker, Jason ^a   Wylie, Todd ^a   Magrini, Vincent ^a   Griffith, Malachi ^a   Griffith, Obi L ^a   Ly, Amy ^a   Ellisman, Mark H ^b   Mardis, Elaine R ^a   Gutmann, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GROWTH FACTOR; MINOCYCLINE; NEUTRALIZING ANTIBODY; RANTES; CCL5 PROTEIN, HUMAN; MESSENGER RNA;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CHILD; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GLIOMA; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INFANT; MACROPHAGE; MALE; MICROGLIA; MONOCYTE; MOUSE; NEUROFIBROMATOSIS TYPE 1; NEWBORN; NONHUMAN; OPTIC NERVE; OPTIC NERVE GLIOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETINA DISEASE; RNA SEQUENCE; SOLID TUMOR; TUMOR MICROENVIRONMENT; ANIMAL; ASTROCYTE; BRAIN TUMOR; C57BL MOUSE; CYTOLOGY; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HIGH THROUGHPUT SEQUENCING; MAMMALIAN EMBRYO; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADOLESCENT; ANIMALS; ASTROCYTES; BLOTTING, WESTERN; BRAIN NEOPLASMS; CHEMOKINE CCL5; CHILD; CHILD, PRESCHOOL; EMBRYO, MAMMALIAN; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NEUROFIBROMATOSIS 1; OPTIC NERVE GLIOMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 84963964175     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2015.10.002     Document Type: Article

References (100)

1. Tremblay G. Stromal aspects of breast carcinoma. Exp Mol Pathol 1979, 31(1):248-260.
2. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972, 175(3):409-416.
3. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10(2):145-147.
4. Pechman K.R., Donohoe D.L., Bedekar D.P., Kurpad S.N., Schmainda K.M. Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume. Magn Reson Med 2012, 68(4):1266-1272.
5. Gutmann D.H., McLellan M.D., Hussain I., Wallis J.W., Fulton L.L., Fulton R.S., et al. Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res 2013, 23(3):431-439.
6. Morantz R.A., Wood G.W., Foster M., Clark M., Gollahon K. Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors. J Neurosurg 1979, 50(3):305-311.
7. Rossi M.L., Hughes J.T., Esiri M.M., Coakham H.B., Brownell D.B. Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol 1987, 74(3):269-277.
8. Simmons G.W., Pong W.W., Emnett R.J., White C.R., Gianino S.M., Rodriguez F.J., et al. Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth. J Neuropathol Exp Neurol 2011, 70(1):51-62.
9. Roggendorf W., Strupp S., Paulus W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol 1996, 92(3):288-293.
10. Bettinger I., Thanos S., Paulus W. Microglia promote glioma migration. Acta Neuropathol 2002, 103(4):351-355.
11. Yongjun Y., Shuyun H., Lei C., Xiangrong C., Zhilin Y., Yiquan K. Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression. J Neuroimmunol 2013, 260(1-2):1-8.
12. Fonseca A.C., Romao L., Amaral R.F., Assad Kahn S., Lobo D., Martins S., et al. Microglial stress inducible protein 1 promotes proliferation and migration in human glioblastoma cells. Neuroscience 2012, 200:130-141.
13. Markovic D.S., Vinnakota K., Chirasani S., Synowitz M., Raguet H., Stock K., et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A 2009, 106(30):12530-12535.
14. Blacher E., Ben Baruch B., Levy A., Geva N., Green K.D., Garneau-Tsodikova S., et al. Inhibition of glioma progression by a newly discovered CD38 inhibitor. Int J Cancer 2015, 136(6):1422-1433.
15. Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013, 19(10):1264-1272.
16. Guillamo J.S., Creange A., Kalifa C., Grill J., Rodriguez D., Doz F., et al. Prognostic factors of CNS tumours in neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 2003, 126(Pt 1):152-160.
17. Legius E., Marchuk D.A., Collins F.S., Glover T.W. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 1993, 3(2):122-126.
18. Bajenaru M.L., Hernandez M.R., Perry A., Zhu Y., Parada L.F., Garbow J.R., et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003, 63(24):8573-8577.
19. Kim K.Y., Ju W.K., Hegedus B., Gutmann D.H., Ellisman M.H. Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Neuroscience 2010, 170(1):178-188.
20. Chen Y.H., McGowan L.D., Cimino P.J., Dahiya S., Leonard J.R., Lee da Y., et al. Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. Cell Rep 2015, 10(11):1899-1912.
21. Daginakatte G.C., Gianino S.M., Zhao N.W., Parsadanian A.S., Gutmann D.H. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res 2008, 68(24):10358-10366.
22. Daginakatte G.C., Gutmann D.H. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 2007, 16(9):1098-1112.
23. Pong W.W., Higer S.B., Gianino S.M., Emnett R.J., Gutmann D.H. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann Neurol 2013, 73(2):303-308.
24. Pong W.W., Walker J., Wylie T., Magrini V., Luo J., Emnett R.J., et al. F11R is a novel monocyte prognostic biomarker for malignant glioma. PLoS One 2013, 8(10):e77571.
25. Tariq M.A., Kim H.J., Jejelowo O., Pourmand N. Whole-transcriptome RNAseq analysis from minute amount of total RNA. Nucleic Acids Res 2011, 39(18):e120.
26. Cabanski C.R., Magrini V., Griffith M., Griffith O.L., McGrath S., Zhang J., et al. cDNA hybrid capture improves transcriptome analysis on low-input and archived samples. J Mol Diagn 2014, 16(4):440-451.
27. Solga A.C., Pong W.W., Walker J., Wylie T., Magrini V., Apicelli A.J., et al. RNA-sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease. Glia 2014, 63(4):531-548.
28. Zhu Y., Romero M.I., Ghosh P., Ye Z., Charnay P., Rushing E.J., et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 2001, 15(7):859-876.
29. Bajenaru M.L., Zhu Y., Hedrick N.M., Donahoe J., Parada L.F., Gutmann D.H. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol 2002, 22(14):5100-5113.
30. Zhu Y., Harada T., Liu L., Lush M.E., Guignard F., Harada C., et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 2005, 132(24):5577-5588.
31. Hegedus B., Banerjee D., Yeh T.H., Rothermich S., Perry A., Rubin J.B., et al. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res 2008, 68(5):1520-1528.
32. Rodriguez F.J., Ligon A.H., Horkayne-Szakaly I., Rushing E.J., Ligon K.L., Vena N., et al. BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol 2012, 71(9):789-794.
33. Kaul A., Toonen J.A., Gianino S.M., Gutmann D.H. The impact of coexisting genetic mutations on murine optic glioma biology. Neuro-Oncology 2014, 17(5):670-677.
34. Lesche R., Groszer M., Gao J., Wang Y., Messing A., Sun H., et al. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 2002, 32(2):148-149.
35. Yeh T.H., Lee da Y., Gianino S.M., Gutmann D.H. Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. Glia 2009, 57(11):1239-1249.
36. Hegedus B., Dasgupta B., Shin J.E., Emnett R.J., Hart-Mahon E.K., Elghazi L., et al. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell 2007, 1(4):443-457.
37. Garcia J.A., Cardona S.M., Cardona A.E. Isolation and analysis of mouse microglial cells. Curr Protoc Immunol 2014, 104. [Unit 14 35].
38. Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150(6):1121-1134.
39. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361(11):1058-1066.
40. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482(7385):400-404.
41. Trapnell C., Pachter L., Salzberg S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009, 25(9):1105-1111.
42. Roberts A., Pimentel H., Trapnell C., Pachter L. Identification of novel transcripts in annotated genomes using RNA-Seq. Bioinformatics 2011, 27(17):2325-2329.
43. Roberts A., Trapnell C., Donaghey J., Rinn J.L., Pachter L. Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol 2011, 12(3):R22.
44. Trapnell C., Williams B.A., Pertea G., Mortazavi A., Kwan G., van Baren M.J., et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010, 28(5):511-515.
45. Kaul A., Toonen J.A., Gianino S.M., Gutmann D.H. The impact of coexisting genetic mutations on murine optic glioma biology. Neuro Oncol 2014, 17(6):843-853.
46. Rodriguez E.F., Scheithauer B.W., Giannini C., Rynearson A., Cen L., Hoesley B., et al. PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol 2011, 121(3):407-420.
47. Walker F.R., Beynon S.B., Jones K.A., Zhao Z., Kongsui R., Cairns M., et al. Dynamic structural remodelling of microglia in health and disease: a review of the models, the signals and the mechanisms. Brain Behav Immun 2014, 37:1-14.
48. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308(5726):1314-1318.
49. Doorn K.J., Goudriaan A., Blits-Huizinga C., Bol J.G., Rozemuller A.J., Hoogland P.V., et al. Increased amoeboid microglial density in the olfactory bulb of Parkinson's and Alzheimer's patients. Brain Pathol 2014, 24(2):152-165.
50. Kremlev S.G., Roberts R.L., Palmer C. Differential expression of chemokines and chemokine receptors during microglial activation and inhibition. J Neuroimmunol 2004, 149(1-2):1-9.
51. Huettner C., Czub S., Kerkau S., Roggendorf W., Tonn J.C. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 1997, 17(5A):3217-3224.
52. Goswami S., Gupta A., Sharma S.K. Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J Neurochem 1998, 71(5):1837-1845.
53. Berdel W.E., de Vos S., Maurer J., Oberberg D., von Marschall Z., Schroeder J.K., et al. Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene. Cancer Res 1992, 52(12):3498-3502.
54. Li W., Graeber M.B. The molecular profile of microglia under the influence of glioma. Neuro Oncol 2012, 14(8):958-978.
55. Koochekpour S., Jeffers M., Rulong S., Taylor G., Klineberg E., Hudson E.A., et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997, 57(23):5391-5398.
56. Campanella M., Sciorati C., Tarozzo G., Beltramo M. Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke 2002, 33(2):586-592.
57. Henriquez N.V., Forshew T., Tatevossian R., Ellis M., Richard-Loendt A., Rogers H., et al. Comparative expression analysis reveals lineage relationships between human and murine gliomas and a dominance of glial signatures during tumor propagation in vitro. Cancer Res 2013, 73(18):5834-5844.
58. Lambert S.R., Witt H., Hovestadt V., Zucknick M., Kool M., Pearson D.M., et al. Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. Acta Neuropathol 2013, 126(2):291-301.
59. Solga A.C., Gianino S.M., Gutmann D.H. NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. Oncogene 2014, 33(3):289-299.
60. Proudfoot A.E., Power C.A., Hoogewerf A.J., Montjovent M.O., Borlat F., Offord R.E., et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996, 271(5):2599-2603.
61. Proudfoot A.E., Buser R., Borlat F., Alouani S., Soler D., Offord R.E., et al. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem 1999, 274(45):32478-32485.
62. Huang Y., Jiao S., Tao X., Tang Q., Jiao W., Xiao J., et al. Met-CCL5 represents an immunotherapy strategy to ameliorate rabies virus infection. J Neuroinflammation 2014, 11(1):146.
63. Plater-Zyberk C., Hoogewerf A.J., Proudfoot A.E., Power C.A., Wells T.N. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 1997, 57(1-3):117-120.
64. Shahrara S., Proudfoot A.E., Woods J.M., Ruth J.H., Amin M.A., Park C.C., et al. Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum 2005, 52(6):1907-1919.
65. Wong M., Uddin S., Majchrzak B., Huynh T., Proudfoot A.E., Platanias L.C., et al. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem 2001, 276(14):11427-11431.
66. Zhang Y., Lv D., Kim H.J., Kurt R.A., Bu W., Li Y., et al. A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res 2013, 23(3):394-408.
67. Cambien B., Richard-Fiardo P., Karimdjee B.F., Martini V., Ferrua B., Pitard B., et al. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRbeta in colorectal carcinoma. PLoS One 2011, 6(12):e28842.
68. Glass W.G., Hickey M.J., Hardison J.L., Liu M.T., Manning J.E., Lane T.E. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J Immunol 2004, 172(7):4018-4025.
69. dos Santos A.C., Barsante M.M., Arantes R.M., Bernard C.C., Teixeira M.M., Carvalho-Tavares J. CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis-an intravital microscopy study. J Neuroimmunol 2005, 162(1-2):122-129.
70. Lee J.K., Schuchman E.H., Jin H.K., Bae J.S. Soluble CCL5 derived from bone marrow-derived mesenchymal stem cells and activated by amyloid beta ameliorates Alzheimer's disease in mice by recruiting bone marrow-induced microglia immune responses. Stem Cells 2012, 30(7):1544-1555.
71. Schall T.J., Bacon K., Toy K.J., Goeddel D.V. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990, 347(6294):669-671.
72. Skuljec J., Sun H., Pul R., Benardais K., Ragancokova D., Moharregh-Khiabani D., et al. CCL5 induces a pro-inflammatory profile in microglia in vitro. Cell Immunol 2011, 270(2):164-171.
73. Listernick R., Ferner R.E., Liu G.T., Gutmann D.H. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007, 61(3):189-198.
74. Tillie-Leblond I., Hammad H., Desurmont S., Pugin J., Wallaert B., Tonnel A.B., et al. CC chemokines and interleukin-5 in bronchial lavage fluid from patients with status asthmaticus. Potential implication in eosinophil recruitment. Am J Respir Crit Care Med 2000, 162(2 Pt 1):586-592.
75. Raport C.J., Gosling J., Schweickart V.L., Gray P.W., Charo I.F. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem 1996, 271(29):17161-17166.
76. Heath H., Qin S., Rao P., Wu L., LaRosa G., Kassam N., et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997, 99(2):178-184.
77. Pakianathan D.R., Kuta E.G., Artis D.R., Skelton N.J., Hebert C.A. Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. Biochemistry 1997, 36(32):9642-9648.
78. Vago L., Nebuloni M., Bonetto S., Pellegrinelli A., Zerbi P., Ferri A., et al. Rantes distribution and cellular localization in the brain of HIV-infected patients. Clin Neuropathol 2001, 20(4):139-145. [Research Support, Non-U.S. Gov't].
79. Avdoshina V., Biggio F., Palchik G., Campbell L.A., Mocchetti I. Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120. Glia 2010, 58(13):1630-1639.
80. Ovanesov M.V., Ayhan Y., Wolbert C., Moldovan K., Sauder C., Pletnikov M.V. Astrocytes play a key role in activation of microglia by persistent Borna disease virus infection. J Neuroinflammation 2008, 5:50.
81. Lokensgard J.R., Hu S., Sheng W., vanOijen M., Cox D., Cheeran M.C., et al. Robust expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus. J Neurovirol 2001, 7(3):208-219.
82. Vilela M.C., Mansur D.S., Lacerda-Queiroz N., Rodrigues D.H., Lima G.K., Arantes R.M., et al. The chemokine CCL5 is essential for leukocyte recruitment in a model of severe Herpes simplex encephalitis. Ann N Y Acad Sci 2009, 1153:256-263.
83. Maung R., Hoefer M.M., Sanchez A.B., Sejbuk N.E., Medders K.E., Desai M.K., et al. CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120. J Immunol 2014, 193(4):1895-1910.
84. Pham K., Luo D., Liu C., Harrison J.K. CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5. J Neuroimmunol 2012, 246(1-2):10-17.
85. Yun H.M., Park K.R., Park M.H., Kim D.H., Jo M.R., Kim J.Y., et al. PRDX6 promotes tumor development via the JAK2/STAT3 pathway in a urethane-induced lung tumor model. Free Radic Biol Med 2015, 10.
86. Zemskova M.Y., Song J.H., Cen B., Cerda-Infante J., Montecinos V.P., Kraft A.S. Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell Signal 2015, 27(1):135-146.
87. Jehs T., Faber C., Juel H.B., Bronkhorst I.H., Jager M.J., Nissen M.H. Inflammation-induced chemokine expression in uveal melanoma cell lines stimulates monocyte chemotaxis. Invest Ophthalmol Vis Sci 2014, 55(8):5169-5175.
88. Zhang Y., Liao S., Fan W., Wei W., Wang C., Sun S. Tunicamycin-induced ER stress regulates chemokine CCL5 expression and secretion via STAT3 followed by decreased transmigration of MCF-7 breast cancer cells. Oncol Rep 2014, 32(6):2769-2776.
89. Niwa Y., Akamatsu H., Niwa H., Sumi H., Ozaki Y., Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001, 7(2):285-289.
90. Luboshits G., Shina S., Kaplan O., Engelberg S., Nass D., Lifshitz-Mercer B., et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999, 59(18):4681-4687.
91. Mrowietz U., Schwenk U., Maune S., Bartels J., Kupper M., Fichtner I., et al. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer 1999, 79(7-8):1025-1031.
92. Murooka T.T., Rahbar R., Fish E.N. CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem Biophys Res Commun 2009, 387(2):381-386.
93. Tan M.C., Goedegebuure P.S., Belt B.A., Flaherty B., Sankpal N., Gillanders W.E., et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009, 182(3):1746-1755.
94. Sugasawa H., Ichikura T., Kinoshita M., Ono S., Majima T., Tsujimoto H., et al. Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Int J Cancer 2008, 122(11):2535-2541.
95. Vaday G.G., Peehl D.M., Kadam P.A., Lawrence D.M. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006, 66(2):124-134.
96. Mencarelli A., Graziosi L., Renga B., Cipriani S., D'Amore C., Francisci D., et al. CCR5 antagonism by maraviroc reduces the potential for gastric cancer cell dissemination. Transl Oncol 2013, 6(6):784-793.
97. Hattermann K., Sebens S., Helm O., Schmitt A.D., Mentlein R., Mehdorn H.M., et al. Chemokine expression profile of freshly isolated human glioblastoma-associated macrophages/microglia. Oncol Rep 2014, 32(1):270-276.
98. Salmaggi A., Gelati M., Pollo B., Frigerio S., Eoli M., Silvani A., et al. CXCL12 in malignant glial tumors: a possible role in angiogenesis and cross-talk between endothelial and tumoral cells. J Neurooncol 2004, 67(3):305-317.
99. Kenig S., Alonso M.B., Mueller M.M., Lah T.T. Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9. Cancer Lett 2010, 289(1):53-61.
100. Coniglio S.J., Eugenin E., Dobrenis K., Stanley E.R., West B.L., Symons M.H., et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med 2012, 18:519-527.